An association between dietary fat intake and the incidence of multiple sclerosis was first proposed by Swank in 1950 . ' Sinclair' later suggested that a deficient intake in polyunsaturated fatty acids might be the link. In line with Sinclair's views, reduced levels of linoleic acid in the serum, erythrocytes, lymphocytes and platelets of patients with multiple sclerosis have been reported."4 The addition of linoleic acid to the diet of healthy people rapidly increases serum linoleic acid' and an initial doubleblind trial of dietary supplementation with sunflower seed oil emulsion showed that the relapses of treated patients were less severe and of shorter duration than in the placebo group taking oleic acid."5 This initial report was supported by a second larger study" though not by a subsequent report from Canada."'
The data from these three double-blind studies have since been re-analysed '8 Received 16 February 1988 and in revised form 11 July 1988 . Accepted 21 July 1988 whom data were available over a two and a half year period. It was concluded that, among patients who at entry to the trial had minor disability, those treated with linoleic acid showed less deterioration than controls. The earlier findings of reduced severity and duration of relapses were confirmed for all treated patients, particularly for those with short disease duration.
Various suggestions have been made to explain these effects of polyunsaturated fatty acids ranging from the correction oflinoleic acid levels in the lipid of cell membranes to an effect upon blood viscosity or on the immune system by alteration in lymphocyte membrane lipids or the transformation of polyunsaturated fatty acids into prostaglandins." Polyunsaturated fatty acids are the precursors of prostaglandins and it might be expected that the acids of the n-3 family, which give rise to prostaglandins of the "3" series and their derivatives, would have different effects from those of the n-6 family which give rise to prostaglandins of the "2" series.' Linoleic acid is the parent acid for the n-6 series of acids including arachidonic acid, and alpha-linolenic acid is the parent acid for the n-3 group including eicosapentaenoic acid and docosahexaenoic acid. These latter two acids are A double-blind controlled trial oflong chain n-3 polyunsaturatedfatty acids in treatment of multiple sclerosis 19 plentiful in fish body oil and it was decided to undertake a trial of dietary supplementation with this agent in patients with multiple sclerosis. The trial was double-blind, control patients receiving olive oil which is predominantly oleic acid, a monounsaturated fatty acid which does not alter the levels ofpolyunsaturates in the blood or tissues.
In view of the evidence5 16 of the effects of n-6 fatty acids in the palliation of the disease, all patients were given dietary advice to encourage a low intake of animal fat and a plentiful intake of n-6 polyunsaturated fatty acids. Thus the trial did not incorporate a strictly untreated control group. Both groups had the same baseline dietary adjustment on top of which the trial substance was evaluated.
It was decided that the structure of the trial should be such as to identify with 90% Dietary advice All patients were seen by a dietitian at the start ofthe trial and were provided with advice and a booklet setting out a diet designed to avoid a high intake of animal fat and to ensure a plentiful intake of n-6 polyunsaturated fatty acids.
Follow-up
Patients were seen at intervals of 3 months and on each occasion a follow-up form was completed by the physician and returned to the trial centre in Newcastle upon Tyne. The trial protocol major outcome criteria were change in overall T _ Treated (n-3, n-6) C _ Controls (n-6). The values represent the amount of each fatty acid as a percentage of the total fatty acid analysed. Standard errors are in all cases less than 5%.
A double-blind controlled trial oflong chain n-3 polyunsaturatedfatty acids in treatment ofmultiple sclerosis 21 At entry (Newcastle) 13 a trend is revealed in that among the mild multiple sclerosis patients the treatment group appeared to deteriorate less than the control group. Of the former 58 8% remained the same or improved compared with only 45-6% of the latter. For patients with multiple sclerosis ofshort duration the proportions were 56-6%
and 42-1% respectively. In neither of these instances is there a statistically significant difference between the two groups.
Analysis of the outcome data shows no significant difference between the three centres. Assessment of frequency (table 4) , duration and severity of relapses, although again showing a trend in favour of the treatment group does not reveal a statistically significant difference.
Fatty acids analysis The assessment of serum fatty acids in the patients in the trial shows that both dietary manipulation and supplementation with fish oil appreciably alters the proportion of certain of the fatty acids. Table 5 shows that in both groups there is an increase in the percentage of linoleic acid though the increase is more marked in the control group. The proportions of eicosapentaenoic and docosahexaenoic acids are significantly increased in the patients given supplements with fish oil capsules and are essentially unchanged in the control group.
Assessment of the adipose tissue has shown similar patterns of change though occurring at a rather later The reason for this minor improvement in the outcome of multiple sclerosis patients with fish oil is uncertain and whether the n-3 polyunsaturated fatty acids act via their role as precursors ofprostaglandins, in cell membranes, on blood viscosity or as part of myelin itself is unknown. It would have been ideal to measure the levels of the Series "2" and Series "3" prostaglandin in this study but the difficulties in organising such assessments and the unavailability of assays precluded such investigation.
Many patients with multiple sclerosis now supplement their diet with polyunsaturated fatty acids in the form of vegetable oils. This study does not provide statistically significant results but there is a trend to indicate that patients with multiple sclerosis should increase their consumption of fish oils.
